In an often-seen routine, the UK's National Institute for Health and Care Excellence (NICE) has rejected a drug maker's novel product on grounds that its proposed patient access scheme doesn't represent value for money; the latest example being Roche’s multiple sclerosis therapy Ocrevus (ocrelizumab).
In the first stage of its review process into Roche's new MS treatment – which reached blockbuster status in its...







